Effects of Nicotinamide Riboside on Metabolism and Vascular Function

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03501433

Enrollment

Registered

2018-04-18

Start date

2018-02-01

Completion date

2019-12-01

Last updated

2020-09-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aging, Lipemia

Keywords

postpandial, lipemia, microvascular

Brief summary

The purpose of this study is to determine the effects of Nicotinamide Riboside (NR) supplementation on metabolism and vascular function following high-fat meal. Differences between young (18-35) and older (60-75) adults will be determined.

Detailed description

The purpose of this study is to determine the effects of 7 days of Nicotinamide Riboside (NR) or placebo supplementation on metabolism and vascular function following high-fat meal. Differences between young (18-35) and older (60-75) adults will be determined.

Interventions

DIETARY_SUPPLEMENTNicotinamide riboside chloride (Niagen)

250 mg capsules 2x/day for 7 days

DIETARY_SUPPLEMENTPlacebo

2x/day for 7 days

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

BASIC_SCIENCE

Masking

DOUBLE (Subject, Outcomes Assessor)

Masking description

I single investigator will be responsible for blinding. All researchers involved in collection and evaluation of data will remain blinded to treatments.

Intervention model description

Randomized, cross-over

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Yes

Inclusion criteria

* Age 18 to 35 (young) and 60 to 75 (older) * Normo- or pre-hypertensive (blood pressure \<140/90 mmHg) * Non-smokers * Able to give informed consent and participate in all laboratory visits

Exclusion criteria

* Currently taking any medications that could interfere with cardiovascular or metabolic outcomes will be excluded from the study (e.g., beta-blockers) * Known metabolic (e.g. Type I or Type II diabetes, cardiovascular disease, etc.) or immunologic (e.g. HIV, cancer, autoimmune, etc.) diseases * Food allergies to egg, milk, soy or wheat * Women who are pregnant or planning to become pregnant during the course of the study, * Pacemaker or other implanted device * Unwilling to participate in the experimental protocol or blood draws will be excluded

Design outcomes

Primary

Measure	Time frame	Description
NAD+	7 days	Blood and peripheral blood mononuclear cell (PBMC) levels

Secondary

Measure	Time frame	Description
Vasodilatory responsiveness	7 days	Post-Occlusion Reactive Hyperemia (PORH)
Lipdemia	7 days	Fasting and postprandial
Oxidative stress and inflammation	7 days	Plasma markers and expression in circulating PBMCs

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026